ReviewBiomedical reports2026
Long non-coding RNA GAS6-AS1 and its molecular mechanisms in human cancer (Review).
Review in Biomedical reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Long non-coding RNAs (lncRNAs) play crucial roles in regulating gene expression and tumor progression. Growth arrest specific 6-antisense RNA 1 (GAS6-AS1), a novel lncRNA located antisense to the GAS6 gene, has been increasingly recognized as an important regulator in multiple cancers. Emerging evidence demonstrates that GAS6-AS1 participates in tumor initiation and progression by functioning as a competitive endogenous RNA that modulates microRNA activity, regulates downstream target genes, and influences key signaling pathways, including Wnt/β-catenin and AXL signaling. Through these mechanisms, GAS6-AS1 affects cancer cell proliferation, migration, invasion, apoptosis, metabolic reprogramming and chemoresistance. GAS6-AS1 exhibits context-dependent functions across different cancer types. GAS6-AS1 predominantly functions as an oncogenic lncRNA in multiple cancers, including colorectal cancer, breast cancer, hepatocellular carcinoma, ovarian cancer, glioma, gastric cancer, renal cell carcinoma and acute myeloid leukemia. In contrast, GAS6-AS1 has been reported to exert tumor-suppressive effects in lung adenocarcinoma. Abnormal expression of GAS6-AS1 is closely associated with tumor progression, metastasis and patient prognosis, highlighting its potential as a diagnostic and prognostic biomarker as well as a therapeutic target. Overall, GAS6-AS1 represents a promising molecule for understanding cancer pathogenesis and developing novel strategies for precision cancer diagnosis and treatment, although further clinical validation and mechanistic studies are still required.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.